Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Radar 84 (high attention) · dilution pressure high · listing risk high · governance risk low · runway cash-flow positive · strongest signal: Hearings panel (Jul 28, 2026)
What would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
What would prove it wrong: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-14 filing | 25 |
| Aug 11, 2026 | ▼ Offering (424B) | 424B5 prospectus supplement 2026-08-11; 0 prior 424B filings in 12m filing | 50 |
| Aug 11, 2026 | ▼ ATM program | “atm” language in 8-K (8-K) filed 2026-08-11 filing | 38 |
| Aug 11, 2026 | ▼ ATM program | “atm” language in 424B5 (424B5) filed 2026-08-11 filing | 38 |
| Aug 11, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-1.1) filed 2026-08-11 filing | 32 |
| Aug 7, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-07 (accepted 16:30 ET) filing | 35 |
| Aug 7, 2026 | ▼ Shelf effective | EFFECT notice 2026-08-07 filing | 21 |
| Jul 31, 2026 | ▼ Shelf filed | S-3 filed 2026-07-31 filing | 35 |
| Jul 31, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-07-31 (accepted 17:21 ET) filing | 35 |
| Jul 31, 2026 | ▼ ATM program | “atm” language in S-3 (S-3) filed 2026-07-31 filing | 34 |
| Jul 28, 2026 | ▼ Hearings panel | “hearings panel” language in 8-K (EX-99.1) filed 2026-07-28 filing | 52 |
| Jul 28, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-99.1) filed 2026-07-28 filing | 32 |
VIVS VivoSim Labs, INC. · DAIC CID Holdco, Inc. · NCRA NOCERA, INC. · GNPX Genprex, Inc. · FLD Fold Holdings, Inc. · HCWB HCW Biologics Inc. · screener →